Insmed provides business update at 42nd annual j.p. morgan healthcare conference

—arikayce® (amikacin liposome inhalation suspension) delivers full-year 2023 revenues exceeding the upper end of guidance range with unaudited global net product sales of approximately $305.2 million— —2024 global arikayce revenues expected to be between $340 million and $360 million, reflecting double-digit growth compared to 2023— —topline data from the phase 3 aspen study of brensocatib in adult patients with bronchiectasis remains on track to read out in the latter part of second-quarter 2024— —enrollment in the phase 2 study of tpip in patients with ph-ild completed in november 2023; topline data expected in second-quarter 2024— bridgewater, n.j. , jan. 5, 2024 /prnewswire/ -- insmed incorporated (nasdaq: insm), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the company's four pillars and outlook for 2024.
INSM Ratings Summary
INSM Quant Ranking